BOSTON and REHOVOT, Israel - Evogene Ltd . (NASDAQ:EVGN) (TASE:EVGN), a computational biology company, and Verb Biotics LLC, a microbiome health ingredient firm, have announced a collaboration to develop new probiotic strains. These strains are expected to produce sustainable quantities of microbial metabolites, which are beneficial for human health and vitality. The partnership will leverage Evogene's MicroBoost AI tech-engine and Verb Biotics' microbiome expertise to identify and enhance genetic pathways in microbes.
The probiotics market is projected to grow to $114B by 2031, doubling from its $55B value in 2022. This growth is driven by increased awareness of the microbiome's role in health. The collaboration aims to create synergies by combining Evogene's AI technology with Verb Biotics' genomic knowledge to innovate in the field of probiotics.
Noah Zimmerman, CTO of Verb Biotics, expressed that the partnership with Evogene will provide a significant advantage in developing microbiome-driven health solutions. Eyal Ronan, EVP of Business Development at Evogene, highlighted the strategic importance of the collaboration in expanding the use of their AI tech-engine to new life sciences sectors.
The financial details of the agreement were not disclosed. Both companies are optimistic about the potential of their combined efforts to advance probiotic innovation.
This news is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.